TransMedics Group Management
Management criteria checks 4/4
TransMedics Group's CEO is Waleed Hassanein, appointed in Aug 1998, has a tenure of 26.58 years. total yearly compensation is $6.76M, comprised of 9.4% salary and 90.6% bonuses, including company stock and options. directly owns 1.76% of the company’s shares, worth $39.63M. The average tenure of the management team and the board of directors is 4 years and 11.6 years respectively.
Key information
Waleed Hassanein
Chief executive officer
US$6.8m
Total compensation
| CEO salary percentage | 9.4% |
| CEO tenure | 26.6yrs |
| CEO ownership | 1.8% |
| Management average tenure | 4yrs |
| Board average tenure | 11.6yrs |
Recent management updates
Recent updates
TransMedics: Aggressive Guidance Largely Ignored By The Market
Mar 03TransMedics: Big Growth And Operational Advantages, Buy This Leading Medical Player
Feb 23TransMedics Group, Inc.'s (NASDAQ:TMDX) 26% Jump Shows Its Popularity With Investors
Feb 16
Returns Are Gaining Momentum At TransMedics Group (NASDAQ:TMDX)
Jan 19TransMedics: Misplaced Fear
Jan 16Breaking Into Healthcare: Why TransMedics Is My Bold First Move
Jan 05With A 30% Price Drop For TransMedics Group, Inc. (NASDAQ:TMDX) You'll Still Get What You Pay For
Dec 28TransMedics Faces Market Turbulence As Growth Engines Stutter
Dec 04These 4 Measures Indicate That TransMedics Group (NASDAQ:TMDX) Is Using Debt Reasonably Well
Nov 20TransMedics: Long-Term Thesis Hasn't Changed At All
Nov 19TransMedics: Overreaction To Temporary Headwinds (Rating Upgrade)
Nov 12What You Can Learn From TransMedics Group, Inc.'s (NASDAQ:TMDX) P/S After Its 44% Share Price Crash
Oct 30TransMedics: Mistakes Have Been Made, Here's My Updated Outlook
Oct 29TransMedics' Organ Care: Critical Innovation With Lofty Expectations
Oct 23TransMedics Group: This Could Be One Of The Biggest Moats In A Decade
Oct 16Returns Are Gaining Momentum At TransMedics Group (NASDAQ:TMDX)
Sep 18TransMedics: Take Profits While The Valuation Is Sky High
Sep 18TransMedics: Wide Moat Player At A Lower Valuation Than Peers
Sep 10TransMedics Group, Inc.'s (NASDAQ:TMDX) P/S Is Still On The Mark Following 25% Share Price Bounce
Aug 28TransMedics: Heart And Lungs Will Drive The Next Leg Higher
Aug 19Analysts Just Made A Meaningful Upgrade To Their TransMedics Group, Inc. (NASDAQ:TMDX) Forecasts
Aug 06TransMedics Group: Providing Long-Term Detailed Forecast And Upgrading To Buy
Aug 04TransMedics Group, Inc. Just Recorded A 66% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 02TransMedics Group Stock: Too Far, Too Fast
Jul 08TransMedics: NOP, Logistics And Transport Are Key Growth Drivers But Stock Is Pricey
Jun 17TransMedics Group (NASDAQ:TMDX) Might Have The Makings Of A Multi-Bagger
Jun 10TransMedics: Transportation Supporting Growth
May 21TransMedics Group: Looking At The Road Ahead After An Exceptional Q1 (Rating Downgrade)
May 06TransMedics Group, Inc. (NASDAQ:TMDX) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Apr 24TransMedics Group: Founder Led Company With Solid Potential
Apr 19Is TransMedics Group (NASDAQ:TMDX) Using Too Much Debt?
Apr 11TransMedics Group: Emerging Medical Device Market Leader With A Long Growth Runway
Mar 19TransMedics Group: Huge Opportunity In Organ Transplants
Mar 12TransMedics: A Very Expensive Growth Stock
Feb 07With TransMedics Group, Inc. (NASDAQ:TMDX) It Looks Like You'll Get What You Pay For
Jan 23Calculating The Fair Value Of TransMedics Group, Inc. (NASDAQ:TMDX)
Jan 02Does TransMedics Group (NASDAQ:TMDX) Have A Healthy Balance Sheet?
Nov 05This Just In: Analysts Are Boosting Their TransMedics Group, Inc. (NASDAQ:TMDX) Outlook for This Year
Aug 06TransMedics Group (NASDAQ:TMDX) Has Debt But No Earnings; Should You Worry?
Aug 02TransMedics Group, Inc. (NASDAQ:TMDX) Not Lagging Industry On Growth Or Pricing
Jun 29Brokers Are Upgrading Their Views On TransMedics Group, Inc. (NASDAQ:TMDX) With These New Forecasts
May 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | n/a | n/a | US$35m |
| Sep 30 2024 | n/a | n/a | US$33m |
| Jun 30 2024 | n/a | n/a | US$3m |
| Mar 31 2024 | n/a | n/a | -US$10m |
| Dec 31 2023 | US$7m | US$634k | -US$25m |
| Sep 30 2023 | n/a | n/a | -US$36m |
| Jun 30 2023 | n/a | n/a | -US$18m |
| Mar 31 2023 | n/a | n/a | -US$28m |
| Dec 31 2022 | US$3m | US$575k | -US$36m |
| Sep 30 2022 | n/a | n/a | -US$42m |
| Jun 30 2022 | n/a | n/a | -US$48m |
| Mar 31 2022 | n/a | n/a | -US$47m |
| Dec 31 2021 | US$7m | US$535k | -US$44m |
| Sep 30 2021 | n/a | n/a | -US$38m |
| Jun 30 2021 | n/a | n/a | -US$30m |
| Mar 31 2021 | n/a | n/a | -US$28m |
| Dec 31 2020 | US$2m | US$534k | -US$29m |
| Sep 30 2020 | n/a | n/a | -US$32m |
| Jun 30 2020 | n/a | n/a | -US$35m |
| Mar 31 2020 | n/a | n/a | -US$36m |
| Dec 28 2019 | US$3m | US$449k | -US$34m |
| Sep 28 2019 | n/a | n/a | -US$32m |
| Jun 29 2019 | n/a | n/a | -US$29m |
| Mar 30 2019 | n/a | n/a | -US$26m |
| Dec 29 2018 | US$524k | US$384k | -US$24m |
Compensation vs Market: Waleed's total compensation ($USD6.76M) is about average for companies of similar size in the US market ($USD5.49M).
Compensation vs Earnings: Waleed's compensation has been consistent with company performance over the past year.
CEO
Waleed Hassanein (56 yo)
26.6yrs
Tenure
US$6,758,070
Compensation
Dr. Waleed H. Hassanein, M.D. is the Founder of Transmedics Group, Inc. and has been its President, Chief Executive Officer and Director since August 1998. He Founded TransMedics, Inc. in August 1998 and h...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 26.6yrs | US$6.76m | 1.76% $ 39.6m | |
| Senior Vice President of Supply Chain & Operations | 2.2yrs | US$2.52m | 0.10% $ 2.3m | |
| Senior VP | 1.7yrs | US$2.35m | 0.0056% $ 125.5k | |
| Chief Commercial Officer | 19.2yrs | US$2.63m | 0.11% $ 2.4m | |
| Chief Financial Officer | less than a year | no data | 0.047% $ 1.1m | |
| Vice President of Global Regulatory Affairs | 5.8yrs | US$813.47k | no data |
4.0yrs
Average Tenure
55.5yo
Average Age
Experienced Management: TMDX's management team is considered experienced (4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 26.6yrs | US$6.76m | 1.76% $ 39.6m | |
| Independent Director | 22.2yrs | US$220.28k | 0.90% $ 20.4m | |
| Independent Director | 4.2yrs | US$238.62k | 0.0035% $ 79.9k | |
| Independent Chairman | 14.2yrs | US$262.32k | 0.52% $ 11.7m | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Independent Director | 9.1yrs | US$232.26k | 0.0022% $ 49.0k | |
| Independent Director | 8.6yrs | US$237.74k | 0.0035% $ 79.9k |
11.6yrs
Average Tenure
70.5yo
Average Age
Experienced Board: TMDX's board of directors are seasoned and experienced ( 11.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/13 23:06 |
| End of Day Share Price | 2025/03/13 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
TransMedics Group, Inc. is covered by 12 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Rescott | Baird |
| William Plovanic | Canaccord Genuity |
| Kristen Stewart | CL King & Associates, Inc. |